Acticor Biotech: Phase 2/3 study fails - MarketScreener : vi

Acticor Biotech announced on Thursday that a Phase 2/3 clinical trial had failed to meet its endpoints in the treatment of stroke, resulting in a suspension of its share price.The biopharmaceutical...

Related Keywords

Yannick Pletan , , Acticor Biotech , Chief Operating Officer , Chief Medical Officer , Markets ,